Cornerstone Capital Management Holdings LLC. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,135 shares of the company’s stock after selling 17,570 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in IDEXX Laboratories were worth $2,352,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of IDXX. D.A. Davidson & CO. increased its position in shares of IDEXX Laboratories by 160.4% during the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after purchasing an additional 385 shares during the period. Sun Life Financial INC increased its position in shares of IDEXX Laboratories by 9,085.7% during the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after purchasing an additional 636 shares during the period. BB&T Investment Services Inc. bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $104,000. Coastline Trust Co bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $202,000. Finally, BB&T Securities LLC bought a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $213,000. 86.60% of the stock is currently owned by institutional investors.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at $157.39 on Wednesday. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77. The company has a market capitalization of $13,730.00, a price-to-earnings ratio of 52.73, a P/E/G ratio of 2.37 and a beta of 0.42. IDEXX Laboratories, Inc. has a one year low of $113.92 and a one year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The business had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 EPS. equities analysts forecast that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

A number of analysts have recently issued reports on IDXX shares. Canaccord Genuity restated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, August 22nd. Bank of America upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective on the stock in a research report on Wednesday, August 23rd. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Stifel Nicolaus restated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Three investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $173.67.

In related news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $148.35, for a total value of $2,670,300.00. Following the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at approximately $157,929,404.55. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,000 shares of company stock worth $16,686,200. 2.77% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/idexx-laboratories-inc-idxx-holdings-reduced-by-cornerstone-capital-management-holdings-llc/1773870.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.